ISSN- O: 2458 - 868X, ISSN–P: 2458 – 8687
Index Copernicus Value: 68 . 16
PubMed - National Library of Medicine - ID: 101731606

International Journal of Medical Science and Innovative Research (IJMSIR)
IJMSIR : A Medical Publication Hub
Available Online at: www.ijmsir.com
Volume – 4, Issue – 4, August - 2019, Page No. : 204 -218

Mitochondrial Disorders and the Replacement Therapies.

[1]Maryam Fatima, [2]Aisha Ateeq, [3]Atiya tulhai, [4]Nazima Begum

[1,2,3]Student, Shadan College of Pharmacy, Rajendranagar mandal, Hyderabad, Telangana

Corresponding Author: Maryam Fatima**,** Students, Shadan College of Pharmacy, Rajendranagar mandal, Hyderabad, Telangana

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Mitochondria are microscopic double membrane bounded cell organelles that are present in eukaryotic cells. They perform several functions such as heat production, calcium storage and regulates cell metabolism. Other than nuclear DNA the only cell organelle which holds its own DNA is mitochondrion. Each human cell contains thousands of copies of mtDNA which at birth are usually all identical a state called homoplasmy. In contrast, individuals with mitochondrial disorders resulting from mtDNA mutations may harbour a mixture of mutant (dysfunctional) and wild-type (abnormal) mtDNA within each cell, and this is called heteroplasmy. Due to this several mitochondrial diseases may occurs, more than 700 diease are known to be associated with mtdna mutations. Some of them includes MELAS, MERF, LEIGH, PEO, optic neuropathy, encephalopathy, optic pigmentosa and many more. There is no actual treatment known till date but can be the mitrochondrial diseases can be controlled among childrens using vitamin cocktails, antioxidant and other supplements. These diseases are carried to offsprings from mother only (maternal inheritance). To avoid the transmission of the diseases to offspring mitochondrial replacement therapies are done in mothers mtDNA.The technique involves the donation of mitochondrial DNA from another healthy mother and nuclearDNA from male and female it is known as three parent inheritance the child gets only 0.3 percent genome of the other mother. There are several techniques which are done in invitro fertilization includes gene therapy, maternal spindle transfer, pronuclear transfer, polar body transfer, genetic bottle neck etc. MRT is the potential for its application for purposes beyond preventing the transmission of serious mtDNA diseases.

Keywords: Heteroplasmy, Encephalopathy, Pigmentosa, Invitro Fertilization, Maternal Spindle Transfer, Pronuclear Transfer.

Introduction

The small circular chromosome encasing mitochondrial DNA (mtDNA) is passed just from mother to offsprings through eggcell. Mitochondrial DNA (mtDNA or mDNA)[1] In humans, mitochondrial DNA of around 16,569 kilobases[2] encode for just 37 genes: 13 for subunits of respiratory buildings I, III, IV and V, 22 for mitochondrial tRNA (for the 20 standard amino acids, in addition to an additional quality for leucine and serine), and 2 for rRNA.(2) One mitochondrion can contain two to ten copies of its DNA.[3] Human mitochondrial DNA was the principal huge piece of the human genome to be sequenced. In many species, including humans, mtDNA is

acquired exclusively from the mother[3] Since mtDNA advances generally gradually contrasted with other genetic markers, it speaks to a backbone of phylogenetics and evolutionary lifescience. Every human cell contains a thousands of copies of mtDNA which during childbirth are normally all identical, an expression called as homoplasmy. An expected 75% of primarily pediatric mitochondrial disorder comes about because of nDNA mutations, which tend to show early and are generally fatal.

Mitochondrial Inheritance

In humans and the vast majority of the multicellular organisms, mtDNA is acquired from the mother (maternally inherited). Mechanism involved for this incorporate basic dilution (an egg contains all things considered 200,000 mtDNA molecules, while a healthy human sperm was accounted for to contain by an average 5 molecules [4,5]), debasement of sperm mtDNA in the male genital tract, in the fertlised egg, and, at any rate in a couple of organisms, results in failure of sperm mtDNA to enter the egg.

Definition of Mitochondrial Disease[6]

Mitochondrial diseases are a clinically heterogeneous gathering of disorders that outcome from a dysfunction in the mitochondrial respiratory chain. The identification of the primary hereditary reason for mitochondrial disease was not known until 1988. Tissues and organs that are exceedingly reliant upon the aerobic metabolism are well on the way to be required in mitochondrial illness.

Prevalence

An expected prevalence of acquired mtDNA disease is 1 in each 5,000-10,000 live births, proposing that, in USA alone, between 1,000 to 4,000 kids are conceived each year with mtDNA diseases. In light of different evaluations, the recurrence of pathogenic mtDNA transformations is significantly higher - 1 in 200 youngsters acquire mutations. In any case, not every one of these youngsters build up the disease at the birth, because of the fact that mtDNA changes are available at low heteroplasmy levels[7]. As per the Research studies it has been concluded that the Prevalence of Pathogenic Mutations of Either mtDNA or nDNA The base point pervasiveness of clinically influenced adults with mitochondrial disease owing to either the mitochondrial or nuclear genome is 12.5 in 100,000 (95% confidence interval (CI) 5 11.1–14.1 3 1025), while the prevalence of every pathogenic mutations in both nDNA and mtDNA is 23 in 100,000 (1 in 4,300; 95% CI 5 14.6–34.5 3 1025)[8].

Clinical Features

Mitochondria are imperative components of every single nucleated cell. Consequently, it is not shocking that mtDNA disease influence many tissues and that the clinical features are so variable Such differing qualities makes it hard to characterize the effect of mtDNA mutations on the health of human, in any case, stratifying the clinical elements into the following groups characterizes the degree of the issue: exemplary mtDNA disorders, clinical disorders with a high risk of mtDNA mutations, contribution common disease phenotypes and mtDNA as an inclination for regular disease and ageing[9].

Common clinical features are ptosis, external ophthalmoplegia, proximal myopathy, exercise intolerance, cardiomyopathy, hyperglycaemia, liver failure, sensorineural deafness, optic atrophy, pigmentary retinal changes and central nervous system findings of fluctuating encephalopathy, seizures, dementia, migraine,stroke-like episodes, ataxia, and spasticity.

Common Mitochondrial Diseases

1. MELAS: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes.

This is the most common type of mitochondrial encephalopathy.

Onset: Usually between 2 and 40 years of age, mean age is 10 years, but can be any age.

Disease characteristics:

Hallmark sign is the 'MELAS' attack. exercise intolerance, seizures, dementia, muscle weakness, hearing loss, blindness, migraine, myopathy, gastric dysmotility, polyneuropathy. **Inheritance:** Maternal

2. MERRF: Myoclonic Epilepsy with Ragged-Red Fibres

Onset: Usually late adolescence to adulthood; variable progression.

Disease characteristics: Myoclonic epilepsy, proximal myopathy, sensorineural deafness, ataxia, pigmentary retinopathy, coordination loss, dementia, distal sensory loss and optic atrophy.

Inheritance: Sporadic or maternal

3. KSS: Kearns-Sayre Syndrome

Onset: Before age 20

Disease characteristics: Progressive External Ophthalmoplegia (PEO) ptosis, pigmentary degeneration of retina, heart block, myopathy, dysphagia most commonly associated with cricopharyngeal achalasia, hearing loss, ataxia, and dementia.

Inheritance: Sporadic

4. Leigh syndrome: Subacute necrotizing encephalomyopathy

Onset: Infancy and progression can be fast or slow. Death often occurs within two years of onset.

Disease characteristics: Vomiting, ataxia, hypotonia or spasticity, seizures, feeding and speech difficulties, hearing loss, nystagmus, visual loss, choreoathetosis, peripheral neuropathy, hyperventilation, motor and intellectual regression.

Inheritance: Mendelian or maternal

5. MNGIE: Mitochondrial Neuro-GastroIntestinal Encephalopathy

Onset: Often before age 20, range five months to 55 years

Disease characteristics: External ophthalmoplegia, ptosis, digestive tract disorders due to viscera neuropathy with weight loss, retinal degeneration, neuropathy, short stature, myopathy, loss of coordination, leukoencephalopathy and hearing loss.

Inheritance: Mendelian

6. NARP: Neuropathy, Ataxia and Retinitis Pigmentosa

Onset: Infancy or childhood

Disease characteristics: Retinitis Pigmentosa causing visual loss, lack of coordination, ataxia, weakness, dementia, seizures and developmental delay. This syndrome may represent a less severe form of MILS (Maternally Inherited Leigh Syndrome).

Inheritance: Maternal

7. PEO: Progressive External Ophthalmoplegia

Onset: Usually in adolescence or early adulthood; slow progression.

Disease characteristics: Gaze limited in all directions, slow eye movements, bilateral, associated with ptosis, slowly progressive, and usually associated with muscle weakness and fatigue.

Inheritance: Maternal, Sporadic, and Mendelian. Often occurs in conjunction with other mitochondrial syndromes.

8. LHON: Leber Hereditary Optic Neuropathy

Onset: Male predominance, usually by 30 years of age, range one to 70 years

Disease characteristics: Visual loss, pre-excitation cardiac conduction syndromes, spasticity, dystonia, 'multiple sclerosis like' disorder and encephalopathy

Inheritance: Maternal



Mitochondrial Symptoms

Since mitochondria are available in all cells, manifestations are available in the majority of organs and over the long haul the conditions get worse than we could have ever envisioned. The principal doubt of a mitochondrial disorder originates from great clinical judgment, not simply monitoring the scope of its numerous manifestations additionally the nature of those also as word[10]. When the word10

Mitochondrial dysfunction is seen in monogenic mitochondrial disorder as well as related with more normal pathologic conditions, for example, alzheimers disease, parkinsons, malignancy, cardiovascular disease, diabetes, epilepsy, hungtintons disease and obesity[(11)]Evolution and origin for the treatment of mitochondrial disease

Mitochondrial disease[often brought about by mutations in mitochondrial DNA (mtDNA)] can show in a scope of extreme side effects, for which there are right now no cures.The maladies are passed from mothers to posterity. Intense research endeavors have focused mainly on a germline therapeutic methodology to prevent the legacy of disease causing on mitochondria.

Early experiments in mice created disease free oocytes by method of mitochondrial replacement (MR): the nucleus fertilized from an oocyte weighed down with mitochondria conveying mtDNA mutations was infused into the cytoplasm of an enucleated donar oocyte that carries mutation free mitochondria. A leap forward in primates came when four macaque children were conceived after MR-aided invitro fertilization(IVF) and when human fetuses survived in place after MR to the blastocyst stage.Thus, the British government appointed the Human Fertilization and Embryology Authority (HFEA) to gather prove with regards to the appropriateness of MR as a restorative and therapeutic approach. The HFEA asked further experiments before clinical utilization of MR [(12).] The U.K. Nuffield Council on Bioethics started a ethical survey of MR and concluded it was ethically acceptable [(13).]

The Medical Research Council and Wellcome Trust of the United Kingdom, who proposed that MR won't influence characteristics ordinarily connected with individual personality [(14).] Accordingly, the four macaques conceived after MR were appeared to be healthy at 3 years old, and specialized challenges have been diminished in human blastocysts [(15)].

Mito and Tracker, the first primates to be produced by spindle-chromosomal complex transfer (ST) into enucleated oocytes.

M Tachibana *et al. Nature* **000**, 1-6 (2009) doi:10.1038/nature08368

Mitochondrial gene replacement in primate offspring and embryonic stem cells Nature 461, 367-372 (17 September 2009)

Alive and well at three years old

M. Tachibana, et al. Towards germline gene therapy of inherited mitochondrial diseases Nature, 493 (2013), pp. 627–631

Differential Diagnosis

Paediatric

- Organic acidaemias: MSUD, propionic, isovaleric, methylmalonic, others

- Urea cycle defects: carbamyl phosphate synthetase deficiency, OTC, citrullinaemia, argininosuccinicaciduria
- Carbohydrate disorders: congenital disorders of glycosylation, galactosaemia, hereditary fructose intolerance
- Aminoacidopathies: homocystinuria, tyrosinemia, nonketotic hyperglycinemia
- Endocrinopathies: CAR, congenital diabetes
- OXPHOS disorders
- Prader-Willi, Angelman syndrome, Rett syndrome

Adult

- Primary endocrine disease
- Vitamin deficiency: B12
- Homocystinuria and associated disorders
- Primary muscle disease: polymyositis, dystrophin associated glycoprotein muscular dystrophies
- Chronic fatigue syndrome
- Autoimmune disorders
- Glycogen storage disorders
- Depression and related psychosomatic disorders
- Other neurodegenerative disorders (MS, Parkinson's, combined systems degeneration)

Table 1. Laboratory tests for investigating mitochondrial disease.

Tests performed before referral	Interpretation
Serum lactate	Useful if elevated but often normal.
Serum CK	May be normal or mildly elevated; patients with very high values (in the thousands) should first be evaluated for other types of myopathies such as polymyositis.
Serum fasting glucose	Diabetes mellitus is a frequent complication of mitochondrial disease.
Serum TSH	Hypothyroidism may mimic some elements of mitochondrial disease.
Other investigations as necessary	The possibility of other more common or treatable disorders considered in the differential diagnosis should be ruled out.
Tests performed after referral to a specialist in mitochondrial disease	
Serum and whole blood acylcarnitine profiles	Can point to a defect in fatty acid oxidation, which can mimic primary dysfunction of the respiratory chain.
Urine organic acids	May show accumulation of metabolites suggesting dysfunction of respiratory chain.

Table 2. Mitochondrial cocktail.

Supplement	Recommended adult dose (p.o.)	Comments	Possible side effects
Coenzyme Q10	30 mg (gel caps or liquid) t.i.d.	Take with food and vitamin C (500 mg b.i.d.)	Nausea, diarrhea, upset stomach, or appetite loss.
L-Carnitine	5 ml (500 mg) b.i.d.	Increases transport of long chain fatty acids into the mitochondria for conversion into energy.	
Creatine monohydrate	2.5 g (powder) b.i.d.	• Creatine supplementation may improve muscle strength by increasing energy stores and prevent accumulation of lactic acid. • Add powder to sugar-free drinks, including hot drinks, but do not boil. Boiling or adding sugar to creatine will increase its conversion to creatinine. • Avoid purchasing creatine manufactured in China.	Occasional mild stomach upset.
Thiamine and riboflavin	100 mg o.d.	• Useful to reduce incidence and severity of migraine headaches in patients with mitochondrial diseases. • Take with large glass of water to increase absorption.	Riboflavin causes urine to turn bright yellow, a harmless side effect.
Alpha lipoic acid	200 mg t.i.d.		• Occasional mild stomach upset. • Very rarely can trigger an allergic skin reaction.
Arginine	500 mg b.i.d.	• Has been shown to reduce stroke-like episodes in MELAS patients. • Check blood levels of arginine 1 month post initiation of oral supplementation. Dose should be titrated to achieve plasma arginine levels of > 80 umol/L.	

Table 3. Monitoring protocol for adult patients with mitochondrial disease.

Assessment	Complication to be identified	Suggested frequency in adults
History and physical exam	Symptoms of myopathy and diabetes; other general presenting symptoms	Annually, although less frequent review may be appropriate for some stable patients
ECG	Conduction defects	Annually
Echocardiogram	Cardiomyopathy	At baseline and then every 3–5 years if baseline is normal
Fasting glucose	Diabetes mellitus	Annually or more frequently if symptoms present
Calcium	Hypocalcemia secondary to hypoparathyroidism	Every 1–2 years or sooner if symptoms present

Treatment

People with MILS might be treated with the administration of thiamine (vitamin B1) or thiamine subsidiaries. A few people with the disorder may experience a brief symptomatic change and slight abating of the movement of the disease.

Extra treatment for these disorders is symptomatic and supportive. For instance, sodium bicarbonate or sodium citrate might be utilized to treat acidosis, antiseizure medications (anticonvulsants) might be utilized to treat seizures, and anticongestive treatment might be important to treat heart variations from the norm. Dystonia might be treated with baclofen, benzhexol, tetrabenezine and gabapentin alone or in blend. Infusions of botulinum poison may likewise be utilized to treat dystonia.

Administrations that advantage individuals who are outwardly disabled may likewise be useful for some affected people. Observing day by day caloric admission and ampleness of eating regimen is prescribed. Psychosocial support for the whole family is basic as well.[16)]

5.4 Purposes of Treatment

To mitigate side effects

To back off the progression of the disease

Effectiveness of Treatment

- Varies from patient to quiet, contingent upon the correct issue and the seriousness of the disorder.
- As a general rule, patients with mild syndrome have a tendency to react to treatment superior to those with extreme.
- In a few conditions, the treatment can be customed specifcally to the patient, and that treatment is effective; though in different conditions, the treatment is "empiric," implying that the treatment makes a sense, however that the benefit of treatment is not clear or ended up being effective. It is impractical to foresee the reaction to vitamins, supplements or eating routine changes before they are tried

Vitamin Coctails And Other Medications

1. Coenzyme Q 10 (CoQ10): This electron acceptor component of the Electron Transport Chain (ETC) is often the base for treatment of mitochondrial disease and has the most data supporting its use.

• Use: Used by cells for production of energy required for basic functioning of cells

• Benefits of therapy: Reactions to therapy vary. It has been shown to improve a variety[(17)]

***2. Idebenone*:** Idebenone is an analogue of coenzyme Q that facilitates electron transfer [(18)].

Uses: has been favourably used in LHON patients. Effects of idebenone on fbroblasts of LHON patients showed marked improvement in the activity of complex I

Benefits: Randomized controlled trial of LHON patients showed marked improvement in visual acuities and visual recovery with idebenone treatment

3. Dichloroacetate: Dichloroacetate (DCA) is more specifically used as a lactic acid lowering agent. It activates the pyruvate dehydrogenase complex by inhibiting the activity of the pyruvate dehydrogenase kinase, which normally phosphorylates and inhibits the enzyme [(19)].

Use: Due to absence of any beneficial effects and potential role in nerve toxicity, DCA is not recommended to patients with MELAS and should be avoided in cases prone to development of peripheral neuropathy.

Vitamins[23]

Compounds which are not made by the body, which are essential for cellular reactions which produce energy. By ensuring that an ample supply of vitamins are accessible to cells they can be utilized to their full extent and help

alleviate many symptoms of mitochondrial disease.

4. Thiamine (Vitamin B1)

Metabolism of carbohydrates to create energy.Proper nervous system functioning, including memory!

5. Riboflavin (Vitamin B2)

Building and maintaining muscle tissues. Maintenance of vision, mucus membranes, skin, nails, and hair

Antioxidants**:** these compounds decrease free radical accumulation which can help improve energy and functioning

6. Alpha Lipoic Acid: Antioxidant which may also increase mitochondrial functioning. Assists with uptake of glucose (which is used for energy) by nerve cells. Approved in Europe for treatment of nerve pain, May help with mental functioning

7. Vitamin C and E

Ability to ward off infection

Absorption of iron

Protects cellular membrane from destruction

Can interfere with medications that treat blood clots such as Warfarin

Supplements

These substances are often utilized to help provide cells with extra energy in order to maintain proper functioning

8. Levocarnitine

Transportation of fatty acids to the mitochondria for energy production

Maintenance of muscle strength and tone.

9. Creatine

Helps improve muscle mass and tone

Thought to help create extra energy in the cells

Improvement in performance of high intensity activities

6.1 Medications to Be Avoided In Mitochondrial Diseases

- Some medications should be taken with caution when you have a mitochondrial disorder.
- Generally to be avoided include: valproic acid, statins, erythromycin, and propofol. Propofol may be safe when given for short periods of time.
- Alcohol and smoking have been known to hasten the progression of some conditions so should be avoided. MSG (monosodium glutamate) can trigger migraine headaches in healthy people, so has the potential is to do the same in those susceptible with mitochondrial disease[26]. Iron can increase free radical production so although excessive amounts should be avoided, a normal diet containing iron is encouraged[20,21.]
- Certain older antiretroviral drugs (anti-HIV drugs) are toxic to mitochondria and should be avoided if possible.
- Doxorubicin, a chemotherapy solution, causes cardiomyopathy as a side effect, in all likelihood through mitochondrial disorders, and ought to be stayed away from.
- Aminoglycoside anti-toxins, for example, gentamicin, amikaycin streptomycin, and tobramycin, can instigate hearing loss by disrupting mitochondria. These anti-toxins ought to be maintained a strategic distance from if the reason for the mitochondrial issue is obscure.
- There are specifc point mutations in the mtDNA that make one more susceptible to hearing damage. Certain antipsychotic medications can increase the risk of diabetes and should be used with caution and frequent monitoring.
- If IV fluids are necessary, Lactated Ringers solution should be avoided as it contains lactic acid which may falsely elevate the lactate reading in blood.

- Some individuals with mitochondrial diseases are more sensitive to volatile anesthetics and need a much lower dose to achieve a bispectral index of <60. Sevoflurane is tolerated better than isoflurane and halothane.

Major Examples of Medications to Avoid In Patients With Mitochondrial Disorders22

Statins	May deplete CoQ10
HIV Medications	Inhibits polymerase gamma (mtDNA depletion)
Metformin	Lactic acidosis due to mitochondrial impairment
Alcohol	Increases oxidative stress, mitochondrial toxin
Smoking and Nicotine Gum/ Patches	Inhibits complex IV, damages mitochondria
Aspirin	Inhibits Mitochondrial Function, Causes Reye Disease In Children

Management

Due to the complexity and chronicity of mitochondrial disease, the role. Of the GP is as team leader, coordinator and supervisor. Also, since

Our medical understanding and general awareness of mitochondrial

Disease is still in its infancy, the GP must be willing to accommodate

These needs for the benefit of the patient:

1. That the physician is interested in learning about a complicated new disease in order to play a more effective role in the patient's care

2. That the physician feels comfortable asking questions and when necessary calling whoever is overseeing the patient's mitochondrial disease management

3. That the physician feels comfortable acting as an advocate for the patient as most medical providers and other services are not familiar with the disease and as a result patients meet many challenges to their care[23].

6.3 Goals For The Treatment

Brain • reduces seizures • improve attention and concentration • improve intellectual functioning • prevent headaches • prevent strokes • improve motor control **Muscle** • improve strength • lessen pain • lessen fatigue • reverse cardiomyopathy **Liver** • improve function , avoid "toxins"	**Nerve** • improve autonomic function • lessen pain • improve nerve conduction **Ears** • prevent further hearing loss **GI** • improve gastric and intestinal motility **Systemic** • encourage growth and so prevent failure to thrive **Eyes** • prevent further retinitis or optic atrophy

7.Mitochondrial replacement Therapies

To prevent such defects in maternal mtDNA from being passed down between generations, researchers have developed a new genetic technique called mitochondrial replacement therapy (MRT).In this in vitro fertilization technique, the mitochondria in an ovum of a woman who carries mtDNA-related disease mutations are destroyed and replaced with healthier ones from a second female donor. The resulting egg is then fertilized with sperm from the intended father to produce an embryo for gestation.

Maternal Spindle Transfer

In 2016, there were several processes that could be used for mitochondrial transfer.[24,25] *One, called* ***maternal*** *spindle transfer* involved taking the nucleus (or spindle of chromosomes) out of the mother's egg and discarding the rest of the mother's egg with the unhealthy (mtDNA). The nucleus of an egg from a donor female was removed leaving an egg with healthy mtDNA. The nucleus of the mother was then inserted into the second egg and fertilized with the sperm of the father. The egg was then placed in the womb of the mother.[26]



Steps[27] :

1. The spindle-chromosome complex is removed as a karyoplast from the provider oocyte and discarded.

2. The spindle-chromosome complex is removed as a karyoplast from the intended mother's oocyte and fused to the provider

oocyte from which the nuclear DNA (nDNA) material has been removed; the intended mother's oocyte is discarded.

3. The reconstructed oocyte contains the intended mother's nDNA and oocyte provider's nonpathogenicmt DNA.

4. The reconstructed oocyte is fertilized by intracytoplasmic sperm injection (ICSI) with the sperm provider's sperm.

5. The fertilized oocyte is cultured in vitro and transferred at the blastocyst stage to the woman who will carry the pregnancy.

Pronuclear Transfer

The pronuclear test is started with the mother's egg which was fertilized with the father's sperm. The nucleus from a female donor's egg was fertilized, extracted and discarded. The fertilized nucleus from the mother was extracted from her egg and the rest of the mother's egg with the unhealthy mtDNA discarded. The fertilised nucleus was transferred to the donor egg with the healthy mtDNA and the egg placed in the mother's womb[28].



Steps:

1. The provider oocyte is fertilized by intracytoplasmic sperms injection (ICSI) with the sperm provider's sperm.

2. The intended mother's oocyte is fertilized by ICSI with the sperm provider's sperm.

3. The male and female pronuclei are removed from the provider zygote and discarded.

4. The male and female pronuclei are removed from the intended mother's zygote and fused to the enucleated provider zygote.The enucleated zygote of the intended mother is discarded.

5. The reconstructed zygote contains male and female nuclear DNA from the intended mother and sperm provider and non-pathogenic mtDNA from the oocyte provider. The zygote is cultured in vitro and transferred at the blastocyst stage to the woman whowould carry the pregnancy.

3.Polar Body Transfer

Polar body genome transfer involved the transfer of polar body genomes from the nucleus and was at a very early stage of development.

A set of techniques for preventing mtDNA disease transmission related methodologically to MST and PNT is polar body 1 transfer (PB1T) and polar body 2 transfer (PB2T)—was recently documented as a potential. Alternative or complementary technique for preventing transmission of mtDNA disease (Wang et al., 2014).



Steps

PB1T and PB2T entail the transfer of the first or second polar body to an enucleated or hemi-enucleated mature oocyte or zygote, respectively. Compared with MST and PNT, PBT has been less rigorously researched and reviewed with respect to the prevention of transmission of mtDNA disease.

PBT could potentially have advantages over MST and PNT, such as reduced mtDNA carryover, the absence of cytoskeletal inhibitors, and less invasive manipulations.

4.Nuclear Genome Transfer

It is as similar to maternal spindle transfer but the eggs were not initially fertilized and were then activated using parthenogenesis. This was a newer procedure but held promise of better success rates.

5.Cytoplasmic transfer used by Cohen and others in 1996-2001 was not regarded as mitochondrial transfer in 2015 . the FDA banned the procedure until a clinical trial could prove its safety. As of 2015 that study had not been conducted, but the procedure was still being used in other countries[29].

Other Techniques and Developments

In addition to MST, PNT, and PBT, there are other current and potential future techniques designed to prevent transmission of mtDNA disease. PGD is a technique performed in the setting of **IVF** to test genetically for a known inherited genetic disease and to allow selection of embryos for transfer to the uterus of the woman who will carry the pregnancy, with the goal of establishing a viable pregnancy and preventing transmission of that disease other than IVF I hetroplasmy and bottleneck.

a) Preimplantation Genetic Diagnosis (PGD) and Screening (PGS)

PGD and PGS are techniques used in conjunction with IVF to test embryos for genetic disorders before intrauterine transfer. PGD involves the performance of diagnostic genetic tests to determine whether specific gene or chromosome disorders—such as a mutation that causes cystic fibrosis or an array that would determine a precise chromosomal abnormality are present or absent in an embryo. In contrast, PGS uses biomarkers to screen for an increased risk that an embryo will harbor any chromosomal abnormality, such as trisomy 21, which causes Down syndrome; a positive biomarker screen would then need to be followed up with a definitive diagnostic test.

The first successful clinical application of PGD was reported in1990 by Handyside et al. (1990) for prevention of transmission of X-linked disorders. The regulation of PGD and PGS is essentially identical to the regulation of IVF. Although PGD and PGS entail laboratory testing. Normally, laboratories that perform diagnostic tests must

be compliant with CLIA to receive Medicare or Medicaid reimbursement.

b) In Vitro Fertilization

Since the 1978 birth of Louise Brown, the first baby conceived by IVF, it is estimated that more than 5 million babies have been born as a result of IVF (ESHRE, 2012). This technology, in which embryos are created outside the body and then implanted, was developed and disseminated with minimal federal oversight.

c) The mitochondrial bottleneck

Entities undergoing uniparental inheritance and with little to no recombination may be expected to be subject to MULLERS RATCHET the accumulation of deleterious mutations until functionality is lost. Animal populations of mitochondria avoid this buildup through a developmental process known as the Mtdna bottleneck. The bottleneck exploits stochastic processes in the cells to increase in the cell-to-cell variabilitythe mutant load as an organism develops: a single egg cell with some proportion of mutant mtDNA thus produces an embryo where different cells have different mutant loads

d) Hetroplasmy

Heteroplasmy shift is an investigational technique that selectively targets and degrades mtDNA containing pathogenic mutations, allowing for repopulation of affected cells with resident, nonpathogenic mtDNA. It has recently has been shown to effectively reduce heteroplasmy levels and prevent transmission of pathogenic mtDNA in mouse and mammalian oocytes and one-cell embryos. As a result, heteroplasmy shift has been proposed as an alternative to MRT for preventing maternal transmission of pathogenic mtDNA mutations that precludes the need for the contribution of a second woman's genetic material (Reddy et al., 2015). Unlike MRT, however, heteroplasmy shift would not be applicable for oocytes or embryos that were homoplasmic or had high heteroplasmy levels for a pathogenic mtDNA, because retaining a certain baseline level of nonpathogenic mtDNA molecules in the cell is essential to enabling repopulation of the mtDNA pool and normal mitochondrial function after degradation of pathogenic mtDNA. A prefatory summary of concepts in reproductive biology and medicine

For example, a cell whose mtDNA consists of 70 percent mutant mtDNA and 30 percent wild-type12 mtDNA is termed heteroplasmic, whereas a cell with 100 percent mutant mtDNA is termed homoplasmic. The concept of heteroplasmy and its relation to mtDNA disease

7.1 Safety: Manipulations and Reagents Used in MRT

This risk could be augmented in MSTgiven that the MII-SCC is not enclosed by a nuclear membrane.[30]

Sendai virus would be used in MST and PNT for fusion of the karyoplast to the recipient oocyte or zygote. Unlike the reagents used in manufacturing processes upstream of MRT, which would be washed away ordiluted in subsequent steps, Sendai virus would be injected directly intothe cell, which would develop into the embryo that would subsequently be transferred into the woman who would carry the pregnancy. There could be unknown risks associated with the immunogenicity of the virus that could adversely affect the embryo or offspring. The cytoskeletal inhibitors used toaid removal of the karyoplast from the oocyte or zygote (e.g., nocodazoleand cytochalasin B) could also pose an unknown risk to the oocyte or zygote.Of note, cytochalasin B would be used in both MST and PNT, and nocodazole would additionally be used in PNT

7.2 Mitochondrial donation

(sometimes called **mitochondrial manipulation technology** or **MMT**) is a special form of invitro

fertilizations in which the future baby's mitochondrial DNA comes from a third party.[31] This technique is used in cases when mothers carry genetic mitochondrial diseases, and conventional in vitro fertilization techniques do not work. mtds often involve energy production issues, and ultimately muscular issues down the road for people affected.[32]

- Currently, mitochondrial donation techniques are legal in the United Kingdom[33] In February 2016, a report was issued by the U.S. Food and Drug administration declaring that further research into mitochondrial donation is ethically permissible. There are many active debates on the matter, as of 2016[34]

7.3 AvailabilityFor Donation

- As of February 2016 in the US there were no regulations governing mitochondrial donation in the US, and Congress had barred the FDA from evaluating any applications that involve implanting modified embryos into a woman.[35]
- China prohibited it after a woman tried to undergo the procedure[36,37] Some research is also taking place in the United States.
- The UK became the first country to legalize the procedure (for women whose eggs have mitochondrial abnormalities) after the Parliament and House of Lords approved The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations in February 2015. This act came into force in October 2015.[38]

Conclusions

Federal regulation would be needed and principled professional society guidelines that interpret the regulations would be helpful to limit the use of MRT to the prevention of transmission of serious, life-threatening mtDNA diseases and to prevent slippage into applications that raise other serious and unresolved ethical issues. . More extensive preclinical research is needed in human oocytes and zygotes, however, to determine the feasibility, efficacy, and safety of PBT and whether these potential advantages would in fact be realized. Entire cytoplasm containing mtDNA in human oocytes can be efficiently replaced by Spindle Transfer and ST is feasible with cryopreserved eggs

Various research reports studied confirmed that MRT are ought to be the prominent carriers for enhancing the Pregnancy and preventing the transmission of diseases from mother to offsprings and providing a painless, effective and safe inherence procedure

Thorough PGD screening for abnormal fertilization is critical for selecting ST embryos for transfers. Thus, it was concluded that, these therapies represented it to be an efficient and superior and human is compatible with normal embryonic development and esc derivation next controlled trials must be carried out for sophisticated production of embryos.

References

1. Sykes, B (10 September 2003). "Mitochondrial DNA and human history". The Human Genome. Wellcome Trust. Archived from the original on 7 September 2015. Retrieved 5 February 2012.
2. Chan DC (2006-06-30). "Mitochondria: Dynamic Organelles in Disease, Aging, and Development". Cell. 125 (7): 1241–1252. doi:10.1016/j.cell.2006.06.010. PMID 16814712.
3. Wiesner RJ, Ruegg JC, Morano I (1992). "Counting target molecules by exponential polymerase chain reaction, copy number of mitochondrial DNA in rat tissues". Biochemical and Biophysical Research Communications. 183 (2): 553–

559. doi:10.1016/0006-291X(92)90517-O. PMID 1550563.

4. Van der Giezen, Mark; Tovar, Jorge; Clark, C. Graham (2005). "MitochondrionDerived Organelles in Protists and Fungi". A Survey of Cell Biology. International Review of Cytology. 244. pp. 175–225. doi:10.1016/S0074-7696(05)44005-X. ISBN 978-0-12-364648-4. PMID 16157181.,
5. Adams, Keith L; Palmer, Jeffrey D (2003). "Evolution of mitochondrial gene content: gene loss and transfer to the nucleus". Molecular Phylogenetics and Evolution. 29 (3): 380–95. doi:10.1016/S1055-7903(03)00194-5. PMID 14615181.
6. Masahito Tachibana1, Paula Amato2, Michelle Sparman1, Joy Woodward1, Dario Melguizo Sanchis1, Hong Ma1, Nuria Marti Gutierrez1, Rebecca Tippner-Hedges1, Eunju Kang1, HyoSang Lee1, Cathy Ramsey1, Keith Masterson2, David Battaglia2, David Lee2, Diana Wu2, Jeffrey Jensen1,3, Phillip Patton2, Sumita Gokhale4, Richard Stouffer1,2, and Shoukhrat Mitalipov1,2 Published in final edited form as: Nature. 2013 January 31; 493(7434): 627–631. doi:10.1038/nature11647. Towards germline gene therapy of inherited mitochondrial diseases
7. Prevalence of Nuclear and Mitochondrial DNA Mutations Related to Adult Mitochondrial Disease Grainne S. Gorman, MRCP, 1,2 Andrew M. Schaefer, MRCP,1,2 Yi Ng, MRCP,1,2 Nicholas Gomez,1,2 Emma L. Blakely, PhD,1,2 Charlotte L. Alston, PhD,1,2 Catherine Feeney,1,2 Rita Horvath, PhD,1,3 Patrick Yu-Wai-Man, PhD,1,3 Patrick F. Chinnery, PhD,1,3 Robert W. Taylor, PhD,1,2 Douglass M. Turnbull, PhD,1,2 and Robert McFarland, PhD1,2
8. MITOCHONDRIAL DNA MUTATIONS IN HUMAN DISEASE Robert W. Taylor and Doug M. Turnbull
9. Mitochondrial Disease Information Booklet for Medical Practitioners Produced by: Dr Karen Crawley MBBS FRACGP Overseen by: Professor Carolyn Sue MBBS PhD FRACP Professor John Cristodoulou MB BS PhD FRACP FRCPA FHGSA Professor David Thorburn BSc(Hons) PhD FHGSA FFS (RCPA).
10. Werner J.H. Koopman, Ph.D., Peter H.G.M. Willems, Ph.D., and Jan A.M. Smeitink, Ph.D.N Engl J Med 2012; 366:1132-1141March 22, 2012DOI: 10.1056/NEJMra1012478 Monogenic Mitochondrial Disorders.
11. Alberts, Bruce; Alexander Johnson; Julian Lewis; Martin Raff; Keith Roberts; Peter Walter (1994). Molecular Biology of the Cell. New York: Garland Publishing Inc. ISBN 0-8153-3218-1
12. Voet, Donald; Judith G. Voet; Charlotte W. Pratt (2006). Fundamentals of Biochemistry, 2nd Edition. John Wiley and Sons, Inc. pp. 547, 556. ISBN 0-471-21495-7.
13. N. Haites, R. Lovell-Badge, “Scientifi c review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception” (HFEA, London, 2011); www.hfea.gov.uk/docs/2011-04-18_Mitochondria_review_-_fi nal_report.PDF.
14. Nuffield Council on Bioethics, Novel Techniques for the Prevention of Mitochondrial DNA Disorders (Nuffield Council on Bioethics, London, 2012), www.nuffi eldbioethics.org/mitochondrial-dna-disorders.

15. D. Paull et al., Nature 493, 632–637 (2013). HFEA, Mitochondria public consultation 2012; www.hfea. gov.uk/6896.html.
16. NORD gratefully acknowledges Sumit Parikh, MD, Neurometabolic and Neurogenetics Staff Clinician, Cleveland Clinic, for assistance in the preparation of the report of Maternally Inherited Leigh Syndrome and NARP Syndrome
17. MitoAction www.mitoaction.org United Mitochondrial Disease Foundation www.umdf.org Medline Plus www.medlineplus.gov a summary of most of vitamin cocktails prescribed for patients with mitochondrial diseae.
18. Nahid Akhtar Khan, Periyasamy Govindaraj, Angamuthu Kannan Meena* & Kumarasamy Thangaraj CSIR-Centre for Cellular & Molecular Biology & *Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India Mitochondrial disorders: Challenges in diagnosis & treatmen Stacpoole PW. The pharmacology of dichloroacetate. Metab Clin Exp 1989; 38 : 1124-44.
19. United Mitochondrial Disease Foundation www.umdf.org
20. Gropman, A.L. (2001) Diagnosis and Treatment of Childhood Mitochondrial Diseases. Current Neurology and Neuroscience Reports. 1: 185-194
21. Exercise and Prevention. Tarnopolsky, M.A., Professor of Pediatrics and Medicine, Rm 2H26, Neuromuscular and Neurometabolic Disease Clinic, 1200 Main St. W., McMaster University Medical Center, Hamilton, Ontario, Canada
22. Dale, Brian; Wilding, Martin; Botta, Giuseppe; Rasile, Marianna; Marino, Marcella; Matteo, Loredana Di; Placido, Giuseppe De; Izzo, Alfredo (2001-07-01). "Pregnancy after cytoplasmic transfer in a couple suffering from idiopathic infertility Case report". Human Reproduction. 16 (7): 1469–1472. doi:10.1093/humrep/16.7.1469. ISSN 0268-1161.
23. The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 No. 572
24. "Three's company". The Economist. 420 (8997). London, UK. 2016-07-09. pp. 68–69. ISSN 0013-0613. Retrieved 2016-07-08.
25. Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations Anne Claiborne, Rebecca English, and Jeffrey Kahn, Editors; Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases; Board on Health Sciences Policy; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine
26. Donaldson, Liam (16 August 2000). "Stem cell research: medical progress with responsibility" (PDF). UK National Archives. UK Department of Health. Retrieved 24 March 2016.
27. Cree, L; Loi, P (January 2015). "Mitochondrial replacement: from basic research to assisted reproductive technology portfolio tool-technicalities and possible risks.". Molecular human reproduction. 21 (1): 3–10. doi:10.1093/molehr/gau082. PMID 25425606.
28. Claiborne, Rebecca English, and Jeffrey Kahn, Editors; Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases; Board on Health Sciences Policy; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine Mitochondrial

Replacement Techniques: Ethical, Social, and Policy Considerations

29. Alleyne, Richard.'Three parent babies' take a step closer to reality, The Telegraph, Nov. 12, 2009., Randerson, James. Scientists seek to create 'three-parent' babiesThe New Scientist Oct. 19. 2004, Three-Parent IVF Set to Go Ahead in Britain, Discover Magazine, June 28, 2013
30. UK approves three-person babies". BBC News. BBC. 24 February 2015. Retrieved 24 February 2015
31. "Britain votes to allow world's first 'three-parent' IVF babies". Reuters. 3 February 2015. Retrieved 3 February 2015.
32. Boseley, Sarah (2010-04-14). "Scientists reveal gene-swapping technique to thwart inherited diseases". London: Guardian. "3 Person IVF". Centre for Genetics and Society. 9 March 2015. 28.Tingley, Kim (27 June 2014). "The Brave New World of Three-Parent I.V.F". The New York Times. Retrieved 2 March 2016
33. Frith, Maxine. Ban on scientists trying to create three-parent baby, The Independent, October 14, 2003.
34. "Now, a three-parent baby". Rediff. 14 October 2003
35. The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 No. 572
36. Knapton, Sarah (25 February 2015) "Three-Parent babies by next year after Lords change the law", The Daily Telegraph, Page 2; A similar article is available on Internet at [1], Retrieved 27 February 2015.